Gain Therapeutics (NASDAQ:GANX) Earns “Outperform” Rating from Oppenheimer

Gain Therapeutics (NASDAQ:GANX)‘s stock had its “outperform” rating reiterated by research analysts at Oppenheimer in a research note issued on Tuesday, Benzinga reports. They presently have a $9.00 price target on the stock. Oppenheimer’s price objective points to a potential upside of 182.13% from the stock’s previous close.

GANX has been the topic of several other reports. Chardan Capital reaffirmed a “buy” rating and issued a $6.00 target price on shares of Gain Therapeutics in a research report on Wednesday, March 27th. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 target price on shares of Gain Therapeutics in a research report on Monday, April 1st.

Gain Therapeutics Stock Down 5.9 %

NASDAQ:GANX opened at $3.19 on Tuesday. The firm has a market capitalization of $51.74 million, a price-to-earnings ratio of -1.87 and a beta of 0.43. Gain Therapeutics has a 1-year low of $2.00 and a 1-year high of $5.65. The company has a current ratio of 3.59, a quick ratio of 3.59 and a debt-to-equity ratio of 0.04. The business’s fifty day moving average price is $4.04 and its 200 day moving average price is $3.44.

Gain Therapeutics (NASDAQ:GANX) last posted its quarterly earnings results on Tuesday, March 26th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.03. On average, sell-side analysts forecast that Gain Therapeutics will post -1.17 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Jeffrey Scott Riley acquired 30,000 shares of the stock in a transaction dated Thursday, March 28th. The shares were acquired at an average price of $3.86 per share, with a total value of $115,800.00. Following the acquisition, the director now owns 30,000 shares in the company, valued at approximately $115,800. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 11.00% of the stock is currently owned by insiders.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of allosteric therapies. Its lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase 1 clinical trial. Its drug discovery platform Magellan identifies novel allosteric binding sites on disease-implicated proteins and exploits untapped opportunities, by pinpointing pockets that cannot be found or drugged with current technologies.